Details of the Drug

General Information of Drug (ID: DMCPF90)

• Drug Name: Mivebresib
• Synonyms: ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]
Multiple myeloma	2A83	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 459.5
  Logarithm of the Partition Coefficient (xlogp); 2.9
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 7
• Chemical Identifiers:
  Formula: C22H19F2N3O4S
  IUPAC Name: N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide
  Canonical SMILES: CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C
  InChI: InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3
  InChIKey: RDONXGFGWSSFMY-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 71600087
  CAS Number: 1445993-26-9
  TTD ID: D0M2TS
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bromodomain and extraterminal domain protein (BET)	TTE4BSY	NOUNIPROTAC	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-2 (PLCH2)	OTYERO80	PLCH2_HUMAN	Gene/Protein Processing	[2]
2-aminomuconic semialdehyde dehydrogenase (ALDH8A1)	OTINY3MW	AL8A1_HUMAN	Gene/Protein Processing	[2]
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 (FUT6)	OTBZUQ7F	FUT6_HUMAN	Gene/Protein Processing	[2]
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1)	OTRI4UR1	CP8B1_HUMAN	Gene/Protein Processing	[2]
Actin-binding LIM protein 2 (ABLIM2)	OT62KOXF	ABLM2_HUMAN	Gene/Protein Processing	[2]
Alanine--glyoxylate aminotransferase (AGXT)	OTIPTH3Q	AGT1_HUMAN	Gene/Protein Processing	[2]
Aldo-keto reductase family 1 member D1 (AKR1D1)	OTBDJ6RL	AK1D1_HUMAN	Gene/Protein Processing	[2]
Alpha-internexin (INA)	OT1D33T4	AINX_HUMAN	Gene/Protein Processing	[2]
Alpha-L-iduronidase (IDUA)	OTTQQ7FN	IDUA_HUMAN	Gene/Protein Processing	[2]
Apolipoprotein L3 (APOL3)	OT95SQHR	APOL3_HUMAN	Gene/Protein Processing	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.